Drugs / Bevacizumab-800CW
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03925285 | May 2019 → Jul 2021 | inverted papilloma | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1 | NCT02975219 | May 2017 → Jan 2019 | endometriosis | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02743975 | Dec 2016 → Feb 2018 | pancreatic adenocarcinoma | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 1/2 | NCT02583568 | Oct 2015 → Jan 2017 | breast cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06809946 | Aug 2026 → Aug 2028 expected | lung neoplasm, lymph node neoplasm, pulmonary coin lesion | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06008522 | Apr → Sep 2024 | Barrett esophagus, colon carcinoma | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevacizumab-800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02583568 ↗ |
| Modality | Diagnostic / imaging agent | “as an Optical Imaging Agent” NCT02583568 ↗ |
| Route | Intravenous | “administered intravenously” NCT02975219 ↗ |
| Target | VEGFA | “VEGF-A-targeting” NCT06008522 ↗ |